Achieve Life Sciences (ACHV) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Wave Life Sciences (WVE) over the past year, gaining 51.9% versus a loss of 59.9%. Over five years, ACHV leads with a -20.4% price change compared with -27.9% for WVE. Achieve Life Sciences is the larger company by market cap ($657.8 million vs $616.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | WVE |
|---|---|---|
| Share price | $6.38 | $3.13 |
| Market cap | $657.79M | $616.76M |
| 1-day change | -8.46% | -1.88% |
| YTD return | +28.37% | -81.59% |
| 1-year return | +51.90% | -59.92% |
| 5-year return | -20.45% | -27.88% |
| EPS (TTM) | $-1.69 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $42.73M |
| Revenue growth (YoY) | — | -60.55% |
| Net income (latest FY) | $-54.65M | $-204.38M |
| Operating margin | — | -504.09% |
| Net margin | — | -478.33% |
| 52-week high | $8.64 | $21.73 |
| 52-week low | $2.62 | $3.04 |
| Distance from 52-week high | -26.16% | -85.60% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +121.79% | +450.16% |
| Average volume | 1.41M | 3.17M |
| Shares outstanding | 103.10M | 197.05M |
| Employees | 28 | 317 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACHV has outperformed WVE by 111.8 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Healthcare · Biotechnology · 28 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Healthcare · Biotechnology · 317 employees
ACHV vs WVE FAQ
Which is bigger, Achieve Life Sciences or Wave Life Sciences?
Achieve Life Sciences (ACHV) is larger, with a market capitalization of $657.79M compared with $616.76M for Wave Life Sciences (WVE).
Which stock has performed better over the past year, ACHV or WVE?
ACHV returned +51.90% over the past 12 months, compared with -59.92% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.